United States v. Ankita Singh

CourtCourt of Appeals for the Sixth Circuit
DecidedAugust 8, 2025
Docket24-3655
StatusPublished

This text of United States v. Ankita Singh (United States v. Ankita Singh) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Ankita Singh, (6th Cir. 2025).

Opinion

RECOMMENDED FOR PUBLICATION Pursuant to Sixth Circuit I.O.P. 32.1(b) File Name: 25a0216p.06

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT

┐ UNITED STATES OF AMERICA, │ Plaintiff-Appellee, │ > No. 24-3655 │ v. │ │ ANKITA SINGH, │ Defendant-Appellant. │ ┘

Appeal from the United States District Court for the Northern District of Ohio at Toledo. No. 3:22-cr-00228-1—Jack Zouhary, District Judge.

Argued: July 30, 2025

Decided and Filed: August 8, 2025

Before: CLAY, GILMAN, and BLOOMEKATZ, Circuit Judges.

_________________

COUNSEL

ARGUED: Andrew P. Lemens, WILLIAMS & CONNOLLY LLP, Washington, D.C., for Appellant. Matthew B. Kall, UNITED STATES ATTORNEY’S OFFICE, Cleveland, Ohio, for Appellee. ON BRIEF: Andrew P. Lemens, Amy Mason Saharia, Clayton P. Phillips, Jason Howell Clayton, WILLIAMS & CONNOLLY LLP, Washington, D.C., for Appellant. Matthew B. Kall, UNITED STATES ATTORNEY’S OFFICE, Cleveland, Ohio, for Appellee. _________________

OPINION _________________

RONALD LEE GILMAN, Circuit Judge. A jury found Dr. Ankita Singh guilty on six counts of healthcare fraud, in violation of 18 U.S.C. § 1347. On appeal, Singh argues that the district court committed three reversible errors. First, she argues that the court incorrectly No. 24-3655 United States v. Singh Page 2

instructed the jury on the meaning of the word “willfully” in the healthcare-fraud statute. She next contends that the court abused its discretion by excluding exculpatory statements made by Singh to an insurance-company investigator that reflected her then-existing state of mind. Finally, Singh argues that the court abused its discretion by allowing lay witnesses to testify that a provider must personally examine a patient in order to determine the medical necessity for certain prescribed equipment.

We find merit in all three of Singh’s arguments. And because these errors were not harmless, we VACATE Singh’s convictions and REMAND for further proceedings consistent with this opinion.

I. BACKGROUND

A. Factual background

In 2018, while working as a hospital physician, Singh was recruited by Barton Associates, a firm that matches physicians with various healthcare companies. Barton introduced Singh to two telehealth companies: Real Time Physicians (Real Time) and Expansion Medical (Expansion). She contracted with both companies between 2019 and 2021 to perform “chart reviews.” During that time, she allegedly believed that she was reviewing and approving medical charts for patients whom other healthcare providers had already evaluated, and who needed durable medical equipment (DME) such as orthotic knee, wrist, and back braces.

A Real Time representative told Singh that the contract position “involves chart reviews in our portal,” that intake would be “done by our clinical staff for you,” and that she would receive guidelines to evaluate whether the DME was medically necessary. “Chart review” is a practice where a physician reviews paperwork and notes generated by another healthcare provider who has personally treated the patient. For both companies, Singh was asked to review and approve completed charts for patients who were purportedly in need of DME. No. 24-3655 United States v. Singh Page 3

Both companies were, in reality, perpetrating a nationwide scheme to defraud Medicare. The companies used paperwork signed by Singh and other physicians to place orders with providers of DME, who in turn submitted claims to Medicare.

On March 4, 2020, Singh received a voicemail from Kristine Whittaker, a representative from Optum Insurance Company, a division of United Health Group that provides insurance plans for Medicare beneficiaries. Singh returned the call 20 minutes later. Whittaker testified at trial that she contacted Singh during her investigation into potentially fraudulent Medicare claims submitted by Quality Lifestyle DME, a company not affiliated with Singh. Singh was not the focus of the investigation, and Optum did not issue a warning to Singh concerning her DME orders.

Whittaker recorded a contemporaneous summary of her conversation with Singh in a call log, prepared and maintained as part of Whittaker’s report concerning her investigation into Quality Lifestyle DME. This summary of the call, which the district court excluded, reads as follows:

Dr. Singh was asked if member [D.B.] was a patient of hers and if she ordered orthotics for her. Dr. Singh said she did not know if [D.B.] was her patient. She was asked if she practiced telehealth and she said yes. She said she worked with Barton Associates and Real Time Physicians. She said she signs into a portal where she gets documents for patients who she believes have been evaluated by another provider. She said she might have signed off on orthotics for [D.B.] (right knee brace with suspension sleeve billed on 10/10/2019). She was under the impression the patients were actually examined because she said the documents appeared to be legitimate. She said she would find document examples and email them and gave her email address.

(Emphasis added.) When Whittaker sent Singh a follow-up email so that Singh could send documents provided by Real Time, Singh promptly forwarded that email to her point of contact at Barton.

One year later, in March 2021, Singh was sent a letter by Humana, another healthcare insurer, containing an informal notice intended to “remind” medical providers of the relevant “rules and regulations surrounding the billing of Medicare claims.” The letter informed Singh that irregularities in her DME orders were “indicative” of potential fraud. Singh promptly No. 24-3655 United States v. Singh Page 4

forwarded the letter to her point of contact at Barton. On May 5, 2021, Barton instructed Singh to stop completing orders for Expansion. Singh stopped performing work for both Expansion and Real Time that same month.

A physician who has examined a patient in need of DME will typically submit a claim to Medicare for the payment of a medical exam corresponding to a subsequent order for DME. But when Singh ordered DME for the patients in question, no claims were ever submitted for a corresponding medical exam. Between 2019 and 2021, Singh ordered 11,769 braces for 3,202 Medicare beneficiaries, and Medicare paid $4,470,931.02 for these items.

No evidence showed that Singh herself ever submitted any order, claim, or request for reimbursement to Medicare, or that she knew the amounts being billed. Singh reported as income on her federal income tax returns all the compensation that she received for completing chart reviews for Real Time and Expansion, which was approximately $78,000 over the roughly three-year period.

B. Procedural background

The grand jury returned an indictment against Singh on six counts of healthcare fraud, in violation of 18 U.S.C. § 1347. A four-day jury trial took place in February 2024.

The government argued that Singh had defrauded Medicare by signing DME orders for patients whom she had not personally evaluated. It called as witnesses six patients for whom Singh had ordered DME. These patients testified that they had never heard of Singh, that they never asked for DME, and yet they still received DME in the mail. The government asked the jury to “infer” that Singh had a criminal intent from the “natural consequences” of her actions. It emphasized the speed with which she had approved the otherwise-completed medical charts, and the fact that she did not personally consult with each patient.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kotteakos v. United States
328 U.S. 750 (Supreme Court, 1946)
Ratzlaf v. United States
510 U.S. 135 (Supreme Court, 1994)
Bryan v. United States
524 U.S. 184 (Supreme Court, 1998)
United States v. Roth
628 F.3d 827 (Sixth Circuit, 2011)
United States v. Poulsen
655 F.3d 492 (Sixth Circuit, 2011)
United States v. Arthur David Lemaster
54 F.3d 1224 (Sixth Circuit, 1995)
United States v. Wali Ahmed Chowdhury
169 F.3d 402 (Sixth Circuit, 1999)
United States v. Steven D. Brawner
173 F.3d 966 (Sixth Circuit, 1999)
United States v. Clarence D. Schreane
331 F.3d 548 (Sixth Circuit, 2003)
United States v. Davis
577 F.3d 660 (Sixth Circuit, 2009)
United States v. Hunt
521 F.3d 636 (Sixth Circuit, 2008)
United States v. Martinez
588 F.3d 301 (Sixth Circuit, 2009)
United States v. Jeffrey Reichert
747 F.3d 445 (Sixth Circuit, 2014)
United States v. Rutigliano, Lesniewski, Baran
790 F.3d 389 (Second Circuit, 2015)
United States v. Paul Volkman
797 F.3d 377 (Sixth Circuit, 2015)
United States v. Kwame Kilpatrick
798 F.3d 365 (Sixth Circuit, 2015)
United States v. Keith Churn
800 F.3d 768 (Sixth Circuit, 2015)
United States v. Mendez
303 F. App'x 323 (Sixth Circuit, 2008)
United States v. Ledinson Chavez
951 F.3d 349 (Sixth Circuit, 2020)
Pfizer, Inc. v. HHS
42 F.4th 67 (Second Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Ankita Singh, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-ankita-singh-ca6-2025.